Biorelevant reactions of the potential anti-tumor agent vanadocene dichloride

Metallomics ◽  
2016 ◽  
Vol 8 (5) ◽  
pp. 532-541 ◽  
Author(s):  
Daniele Sanna ◽  
Maria Serra ◽  
Valeria Ugone ◽  
Laura Manca ◽  
Monica Pirastru ◽  
...  
Keyword(s):  
Vanadocene Dichloride ◽  
Tumor Agent

A Case of Malignant Lymphoma that Healed Completely after Oral Administrations of 4-Hydroxybenzaldehyde

2018 ◽  
Vol 1 (1) ◽  
pp. 01-02
Keyword(s):  
Cancer Patient ◽  
Malignant Lymphoma ◽  
Large Dose ◽  
Side Effect ◽  
Small Dose ◽  
Severe Hemorrhage ◽  
Tumor Agent

In 1969, Mutsuyuki Kochi [1, 2] developed 4-Hydroxybenzaldehyde for use as a novel anti-tumor agent without side effect and patent it. Accordingly, this medicine is capable of preventing carcinogenesis when used in sufficient quantity. To treat advanced cancers, an oncologist should start with giving the cancer patient a small dose of 4-Hydroxybenzaldehyde to avoid the possible severe hemorrhage of a tumor caused by excessive necrosis. Therefore, it has useful applications in treating lymphomas and leukemias. Consequently, those who have these diseases can receive a considerably large dose of the medicine.

scholarly journals Focused ultrasound in neuro-oncology: the role of the Focused Ultrasound Foundation in driving adoption and innovation

2021 ◽  
Author(s):  
Emily C. Whipple ◽  
Camille A. Favero ◽  
Neal F. Kassell
Keyword(s):  
Drug Delivery ◽  
Brain Tumors ◽  
Focused Ultrasound ◽  
Clinical Evidence ◽  
Neurological Injury ◽  
High Concentration ◽  
Potential Applications ◽  
Tumor Agent

Abstract Introduction Intra-arterial (lA) delivery of therapeutic agents across the blood-brain barrier (BBB) is an evolving strategy which enables the distribution of high concentration therapeutics through a targeted vascular territory, while potentially limiting systemic toxicity. Studies have demonstrated lA methods to be safe and efficacious for a variety of therapeutics. However, further characterization of the clinical efficacy of lA therapy for the treatment of brain tumors and refinement of its potential applications are necessary. Methods We have reviewed the preclinical and clinical evidence supporting superselective intraarterial cerebral infusion (SSJACI) with BBB disruption for the treatment of brain tumors. In addition, we review ongoing clinical trials expanding the applicability and investigating the efficacy of lA therapy for the treatment of brain tumors. Results Trends in recent studies have embraced the use of SSIACI and less neurotoxic chemotherapies. The majority of trials continue to use mannitol as the preferred method of hyperosmolar BBB disruption. Recent preclinical and preliminary human investigations into the lA delivery of Bevacizumab have demonstrated its safety and efficacy as an anti-tumor agent both alone and in combination with chemotherapy. Conclusion lA drug delivery may significantly affect the way treatment are delivered to patients with brain tumors, and in particular GBM. With refinement and standardization of the techniques of lA drug delivery, improved drug selection and formulations, and the development of methods to minimize treatment-related neurological injury, lA therapy may offer significant benefits for the treatment of brain tumors.

Insights of Tris(2-pyridylmethyl)amine as anti-tumor agent for osteosarcoma: experimental and in silico studies

2021 ◽  
Vol 1228 ◽  
pp. 129773
Author(s):  
Marcos V. Palmeira-Mello ◽  
Juliana Lima Souza ◽  
Anthuan Ferino Pérez ◽  
Amanda dos Santos Cavalcanti ◽  
Suzana Assad Kahn ◽  
...  
Keyword(s):  
In Silico ◽  
In Silico Studies ◽  
Tumor Agent

Engineered NIR light-responsive bacteria as anti-tumor agent for targeted and precise cancer therapy

2021 ◽  
pp. 130842
Author(s):  
Huizhuo Pan ◽  
Lianyue Li ◽  
Gaoju Pang ◽  
Chunli Han ◽  
Baona Liu ◽  
...  
Keyword(s):  
Cancer Therapy ◽  
Nir Light ◽  
Tumor Agent

Copper(II)-Girard's T complex as a promising anti-tumor agent

2010 ◽  
pp. n/a-n/a
Author(s):  
A. M. A. El-Sokkary ◽  
M. M. El-Naggar ◽  
A. F. Abdel-Aziz ◽  
M. M. Mostafa
Keyword(s):  
T Complex ◽  
Tumor Agent

The anti-tumor agent sagopilone shows antiresorptive effects both in vitro and in vivo

2010 ◽  
Vol 22 (11) ◽  
pp. 2887-2893 ◽  
Author(s):  
A. Strube ◽  
M. I. Suominen ◽  
J. P. Rissanen ◽  
D. Mumberg ◽  
U. Klar ◽  
...  
Keyword(s):  
Tumor Agent

scholarly journals Trimebutine Promotes Glioma Cell Apoptosis as a Potential Anti-tumor Agent

2018 ◽  
Vol 9 ◽  
Author(s):  
Yi-pu Fan ◽  
Pei Liu ◽  
Wei-kang Xue ◽  
Wei-jiang Zhao ◽  
Hong-chao Pan
Keyword(s):  
Cell Apoptosis ◽  
Glioma Cell ◽  
Tumor Agent

The structure of compound 593A, a new anti-tumor agent

Tetrahedron ◽  
1973 ◽  
Vol 29 (18) ◽  
pp. 2743-2746 ◽  
Author(s):  
B.H. Arison ◽  
J.L. Beck
Keyword(s):  
Tumor Agent

Nano-Coated si-SNHG14 Regulated PD-L1 Expression and Decreased Epithelial-Mesenchymal Transition in Nasopharyngeal Carcinoma Cells

2021 ◽  
Vol 17 (10) ◽  
pp. 1993-2002
Author(s):  
Haoran Yu ◽  
Chen Zhang ◽  
Wanpeng Li ◽  
Xicai Sun ◽  
Quan Liu ◽  
...  
Keyword(s):  
Nasopharyngeal Carcinoma ◽  
Epithelial Mesenchymal Transition ◽  
Animal Experiments ◽  
Loss Of Function ◽  
Mesenchymal Transition ◽  
Non Coding Rna ◽  
Long Non Coding Rna ◽  
Tumor Agent

To investigate the expression characteristics of long non-coding RNA SNHG14 in nasopharyngeal carcinoma (NPC) and its effects on epithelial-mesenchymal transition and development of nano-coated si-SNHG14 as an anti-tumor agent. The SNHG14 expression in cancerous and adjacent non-cancerous tissues was monitored using reverse transcriptionpolymerase chain reaction (RT-PCR). Gain- and loss-of-function experiments tested the regulation of SNHG14, miR- 5590-3p, and ZEB1 on PD-L1. The binding association between the above three factors was verified using bioinformatics analysis. EMT-related E-cadherin, N-cadherin, and Vimentin were tested using Western blot. Animal experiments in nude mice verified the function of SNHG14 in the EMT of NPC in vivo. The nano-coated si-SNHG14 was developed as an anti-tumor agent and was verified NPC cell in vitro. SNHG14 was upregulated in NPC tissues. Knocking down SNHG14 markedly inhibited the EMT of NPC. Additionally, the expression of ZEB1 was positively related to that of the SNHG14, while it was inversely correlated with that of miR-5590-3p. Moreover, ZEB1 transcription upregulated PD-L1 and promoted the EMT, while SNHG14 could accelerate the EMT of NPC in vivo by regulating the PD-1 and PD-L1. SNHG14-miR-5590- 3p-ZEB1 positively regulated PD-L1 and facilitate the EMT of NPC. Nano-coated si-SNHG14 significantly downregulated PD-L1 expression and decreased EMT.

Sign in / Sign up

Export Citation Format

Share Document